Marshall Wace
LUMO

Marshall Wace’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Marshall Wace’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,334
Closed -$244K – 1859
2018
Q3 		$244K Buy
+11,334
New +$345K ﹤0.01% 1037

Other funds holding LUMO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's LUMO Position: Q4 2018 in Review

Marshall Wace sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2018, closing a stake of 11,334 shares — an estimated $244K sold.

Marshall Wace first reported a position in LUMO in Q3 2018 and held it in 1 quarter. The position peaked at $244K in Q3 2018. 87 funds tracked by Wall St. Rank hold LUMO as of Q4 2018.

  • Marshall Wace reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Marshall Wace sold 11,334 Lumos Pharma, Inc. Common Stock shares in Q4 2018, an estimated $244K.
  • Marshall Wace first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Marshall Wace's Lumos Pharma, Inc. Common Stock position peaked at $244K in Q3 2018.
  • 87 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2018.

Based on Marshall Wace's 13F filing for Q4 2018, filed 14 Feb 2019.